Additional file 1 of Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial

Wang, Changjun; Lin, Yan; Zhou, Yidong; Mao, Feng; Zhu, Hanjiang; Guan, Jinghong; Zhang, Xiaohui; Shen, Songjie; Huang, Xin; Chen, Chang; Yao, Ru; Zhao, Jialin; Sun, Qiang

doi:10.6084/m9.figshare.12650596.v1

12885_2020_7143_MOESM1_ESM.docx (42.46 kB)

Additional file 1 of Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial

journal contribution

posted on 2020-07-14, 04:36 authored by Changjun Wang, Yan Lin, Yidong Zhou, Feng Mao, Hanjiang Zhu, Jinghong Guan, Xiaohui Zhang, Songjie Shen, Xin Huang, Chang Chen, Ru Yao, Jialin Zhao, Qiang Sun

Additional file 1.

Funding

JiangSu HengRui Medicine

History

Usage metrics

Keywords

Metastatic breast cancer Pyrotinib Aromatase inhibitors Trastuzumab

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

Additional file 1 of Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial

Funding

JiangSu HengRui Medicine

History

Usage metrics

Categories

Keywords

Licence

Exports